About Us

Imago is relentlessly focused on clinical development holding the view that a positive impact on patient outcomes is the ultimate arbiter of progress.

Imago BioSciences is translating true scientific insights into transformative treatments allowing patients to live longer, disease-free lives.

Our initial efforts are aimed at improving the management of proliferative diseases of the bone marrow and activation of the immune system. Diseases of the bone marrow include acute myeloid leukemia, myelodysplastic syndrome, polycythemia vera, myelofibrosis and essential thrombocythemia. These diseases share several features. They are diseases of excessive growth of bone marrow cells whose growth is driven by genetic mutations acquired over the course of a lifetime. They are all diseases that to varying degrees involve inflammation which for some is the defining characteristic.

Imago BioSciences has developed inhibitors of the enzyme lysine-specific demethylase 1 (LSD1). This enzyme plays a critical role is regulating the growth and development of bone marrow cells. Our first inhibitor of LSD1 called IMG-7289 is being tested in patients with acute myeloid leukemia, myelodysplastic syndrome, and myelofibrosis. Future clinical studies are planned for other related diseases.